1. Show article details.

    BRIEF-Novabay Pharmaceuticals Expands Avenova's Geographic Reach To Australia With New Exclusive Distribution Agreement

    Reuters – 7:27 AM ET 11/23/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY PHARMACEUTICALS EXPANDS AVENOVA’S GEOGRAPHIC REACH TO AUSTRALIA WITH NEW EXCLUSIVE DISTRIBUTION AGREEMENT. * NOVABAY PHARMACEUTICALS (NBY) - ANNOUNCES SIGNING OF AGREEMENT WITH PARAGON CARE GROUP AUSTRALIA PTY LTD FOR EXCLUSIVE DISTRIBUTION OF AVENOVA IN AUSTRALIA.

  2. Show article details.

    NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreement

    Business Wire – 6:50 AM ET 11/23/2020

    NovaBay® Pharmaceuticals, Inc., a pharmaceutical company focusing on commercializing Avenova® for the eye care market, announces the signing of an agreement with Paragon Care Group Australia Pty Ltd for the exclusive distribution of Avenova in Australia. “We are delighted to expand the geographic reach of Avenova with this agreement covering Australia,” said Justin Hall, NovaBay CEO.

  3. Show article details.

    BRIEF-NovaBay Reports Q3 Loss Per Share Of $0.08

    Reuters – 4:19 PM ET 11/12/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS. * Q3 LOSS PER SHARE $0.08. * NET PRODUCT REVENUE FOR Q3 OF 2020 WAS $2.2 MILLION, A 34% INCREASE FROM $1.6 MILLION FOR Q3 OF 2019. * REPORTED CASH AND CASH EQUIVALENTS OF $13.4 MILLION AS OF SEPTEMBER 30, 2020 Source text for Eikon: Further company coverage:

  4. Show article details.

    NovaBay Pharmaceuticals Reports Third Quarter 2020 Financial Results

    Business Wire – 4:05 PM ET 11/12/2020

    Conference call begins at 4:30 p.m. Eastern time today EMERYVILLE, Calif. “This is an exceptionally exciting time at NovaBay as Avenova unit sales set a new quarterly record and we prepare for the consumer launch of CelleRx Clinical Reset into the beauty market,” said Justin Hall, President and CEO of NovaBay Pharmaceuticals.

  5. Show article details.

    BRIEF-Novabay Announces Consumer Launch Of Cellerx Clinical Reset

    Reuters – 6:50 AM ET 11/12/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY ANNOUNCES CONSUMER LAUNCH OF CELLERX® CLINICAL RESET™ Source text for Eikon: Further company coverage:

  6. Show article details.

    NovaBay Announces Consumer Launch of CelleRx® Clinical Reset™

    Business Wire – 6:50 AM ET 11/12/2020

    Company enters beauty market with the launch of Clinical Reset as an expansion of the CelleRx brand NovaBay Pharmaceuticals, Inc. (NBY) announces the consumer launch of Clinical Reset, an FDA-cleared skincare product proven to help clean and reduce the buildup of bacteria on facial skin. This press release features multimedia.

  7. Show article details.

    NovaBay Pharmaceuticals to Hold Third Quarter 2020 Conference Call on November 12

    Business Wire – 6:50 AM ET 10/30/2020

    NovaBay® Pharmaceuticals, Inc. announces it will report financial results for the three and nine months ended September 30, 2020 after market close on Thursday, November 12, 2020 and will hold an investment community conference call that day at 4:30 p.m. Eastern time. “I’m excited to share details on a very successful quarter.

  8. Show article details.

    BRIEF-Novabay Pharma Regains Compliance With NYSE American Listing Standards

    Reuters – 7:09 AM ET 10/12/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY PHARMACEUTICALS REGAINS COMPLIANCE WITH NYSE AMERICAN LISTING STANDARDS Source text for Eikon: Further company coverage:

  9. Show article details.

    NovaBay Pharmaceuticals Regains Compliance with NYSE American Listing Standards

    Business Wire – 6:50 AM ET 10/12/2020

    NovaBay® Pharmaceuticals, Inc. announces it believes that it has regained full compliance with the NYSE American’s continued listing standards, subject to NYSE American’s formal confirmation that the Company has regained compliance after the Company files its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020.

  10. Show article details.

    NovaBay Pharmaceuticals Expands Avenova® Consumer Marketing through Affiliate Programs and Enhanced Lifestyle Public Relations

    Business Wire – 6:50 AM ET 09/24/2020

    NovaBay® Pharmaceuticals, Inc. announces expanded Avenova® consumer marketing programs designed to generate greater awareness of its antimicrobial lid and lash spray and promote online sales. NovaBay has engaged PartnerCentric, Inc. for affiliate marketing programs and HVM Communications for enhanced public relations featuring consumer-oriented, lifestyle messaging.

  11. Show article details.

    BRIEF-Novabay Pharmaceuticals Entered First Amendment To That Certain Services Agreement With TLF Bio Innovation Lab

    Reuters – 9:40 AM ET 09/10/2020

    NovaBay Pharmaceuticals Inc (NBY): * NovaBay Pharmaceuticals Inc (NBY) - ENTERED FIRST AMENDMENT TO THAT CERTAIN SERVICES AGREEMENT WITH TLF BIO INNOVATION LAB. * NovaBay Pharmaceuticals Inc (NBY) - AGREED TO AMEND CERTAIN PROVISIONS OF AGREEMENT PRIMARILY RELATED TO EQUITY AWARDS, AND RELATED MILESTONES.

  12. Show article details.

    NovaBay Announces that Avenova is Now Available with “Subscribe & Save”

    Business Wire – 6:50 AM ET 09/08/2020

    Repays Secured Convertible Promissory Note NovaBay® Pharmaceuticals, Inc. announces the availability of “subscribe & save” for repeat orders of Avenova® antimicrobial lid & lash solution on Avenova.com and Amazon.com. “Our upgraded online product listings will allow customers to automate recurring orders, thereby increasing our recurring revenue and improving visibility on future sales,” said J...

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Nov
    12

    NBY announced Q3 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.